Cefprozil

Drug Profile

Cefprozil

Alternative Names: BMY-28100; BMY-28167; Brisoral; Cefzil; Cronocef; Procef

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Antibacterials; Cephalosporins; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Bacterial infections; Respiratory tract infections; Skin and soft tissue infections

Most Recent Events

  • 13 Feb 2013 Cefprozil sublicensed to Swedish Orphan Biovitrum in Austria, Belgium, Ireland, United Kingdom, France, Italy Germany, Spain, Finland, Sweden, Denmark, Norway, Liechtenstein, Netherlands, Portugal, and Luxembourg
  • 31 Dec 2012 Cefprozil licensed to PharmaSwiss in Europe
  • 23 Jul 2008 Bentley Pharmaceuticals has been acquired by Teva Pharmaceutical Industries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top